epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-214, Phase III. Recruiting

Heart failure with reduced ejection fraction

CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.

Which sites are ahead, on target or behind their expectation, where each loses its patients, and what might help.

Sites at a glance

Data to September 30th 2026. Sponsor: Contoso Pharmaceuticals (fictional). Study-level KPIs and QTLs have their own tabs: KPIs and QTLs.

Patients randomised

472 of 824

57% of the target

Sites open

120 of 120

Every planned site is open

Patients screened

843

Up: +88 in the last three months

Sites behind their expectation

60 of 113 judged

Behind 30 ahead, 23 on target, 7 too early to judge

See sites behind

Agreed, of patients approached

55%

55% in published cancer trials

Randomised, of patients screened

56%

The plan assumed 55%

Are enough patients being screened?

Over the last three months the study screened about 29 patients a month; since it began, 56% of patients screened have been randomised. Randomising the remaining 352 by the planned last patient in March 2027 takes about 126 screens a month, 4.3 times the recent pace. At the recent pace the target falls in April 2028.

Screening is behind the plan

Patients screenedCumulative, against the screens the plan implies: its expected randomisations divided by the 55% it expects to pass screening

Show data
Patients screened: planned and actual, by month
MonthPlannedActual
Sep 202300
Dec 202300
Mar 202446
Jun 20243238
Sep 20249480
Dec 2024182155
Mar 2025282257
Jun 2025386356
Sep 2025490451
Dec 2025594529
Mar 2026698646
Jun 2026802727
Sep 2026906823
Oct 2026941843

Sources: epiClinical synthetic screening logs; screen failure by therapeutic area from the planner parameters (D23)

How each kind of site is doing

Each site is compared with what it was expected to recruit in its months open, given its type, track record, country and the protocol. Below 75% of that is behind; above 125% is ahead.

60 out of 113 sites are behind; sites of the same kind differ widely

Patients randomised as a share of those expectedEach dot a site, by profile; log scale; the shaded band is on target

Show data
Each judged site: patients randomised against expected, by profile
SiteProfileRandomisedExpectedObserved ÷ expectedStanding
214-US-01, San DiegoCommunity specialist practice13.7×0.27Behind
214-US-02, Los AngelesSite new to research23.5×0.57Behind
214-US-03, BaltimoreSite new to research43.1×1.30Ahead
214-US-04, AtlantaCommunity specialist practice13.1×0.32Behind
214-US-06, New YorkDedicated research centre25.1×0.39Behind
214-US-08, MiamiDedicated research centre24.9×0.40Behind
214-US-09, NashvilleCommunity hospital84.1×1.94Ahead
214-US-10, ClevelandRegional teaching hospital03.7×0.00Behind
214-US-11, Salt Lake CitySite new to research42.2×1.85Ahead
214-US-12, DallasCommunity specialist practice53.0×1.69Ahead
214-US-13, SeattleRegional teaching hospital25.0×0.40Behind
214-US-14, PhoenixDedicated research centre24.5×0.44Behind
214-US-17, ChicagoSite new to research03.8×0.00Behind
214-US-18, PhiladelphiaDedicated research centre04.3×0.00Behind
214-US-19, PittsburghRegional teaching hospital15.0×0.20Behind
214-US-20, HoustonCommunity hospital84.7×1.71Ahead
214-US-21, San DiegoRegional teaching hospital74.1×1.71Ahead
214-US-22, Los AngelesSite new to research02.9×0.00Behind
214-US-23, BaltimoreCommunity specialist practice03.7×0.00Behind
214-US-24, AtlantaSite new to research12.3×0.44Behind
214-US-25, BostonAcademic medical centre13.8×0.26Behind
214-US-26, New YorkDedicated research centre136.5×2.00Ahead
214-US-27, DenverDedicated research centre54.9×1.01On target
214-US-28, MiamiCommunity hospital83.5×2.30Ahead
214-US-29, NashvilleSite new to research02.6×0.00Behind
214-US-30, ClevelandRegional teaching hospital02.0×0.00Behind
214-US-31, Salt Lake CitySite new to research22.3×0.87On target
214-US-32, DallasDedicated research centre44.5×0.89On target
214-US-33, SeattleDedicated research centre32.4×1.25Ahead
214-US-34, PhoenixCommunity hospital14.9×0.20Behind
214-US-35, MinneapolisDedicated research centre74.8×1.46Ahead
214-US-36, CharlotteCommunity hospital53.4×1.48Ahead
214-US-37, ChicagoCommunity hospital03.1×0.00Behind
214-US-38, PhiladelphiaCommunity hospital03.0×0.00Behind
214-US-39, PittsburghDedicated research centre14.4×0.23Behind
214-UK-01, NottinghamCommunity hospital43.4×1.16On target
214-UK-02, EdinburghRegional teaching hospital24.2×0.48Behind
214-UK-03, LeedsSite new to research32.8×1.07On target
214-UK-04, SheffieldRegional teaching hospital93.9×2.28Ahead
214-UK-05, LondonCommunity hospital75.6×1.25On target
214-UK-06, NewcastleRegional teaching hospital44.5×0.90On target
214-UK-07, BristolSite new to research02.9×0.00Behind
214-UK-08, LiverpoolRegional teaching hospital34.6×0.65Behind
214-UK-09, OxfordSite new to research23.3×0.61Behind
214-UK-10, CardiffRegional teaching hospital64.0×1.49Ahead
214-UK-12, ManchesterAcademic medical centre44.1×0.97On target
214-UK-13, SouthamptonRegional teaching hospital54.5×1.12On target
214-UK-14, BirminghamAcademic medical centre04.5×0.00Behind
214-UK-15, GlasgowCommunity hospital63.9×1.53Ahead
214-ES-01, ZaragozaRegional teaching hospital52.4×2.13Ahead
214-ES-02, PamplonaRegional teaching hospital24.1×0.48Behind
214-ES-03, SalamancaRegional teaching hospital02.2×0.00Behind
214-ES-04, BilbaoSite new to research113.1×3.58Ahead
214-ES-05, MurciaSite new to research63.1×1.95Ahead
214-ES-06, OviedoSite new to research43.3×1.21On target
214-ES-07, ValenciaCommunity hospital25.3×0.38Behind
214-ES-08, SevilleAcademic medical centre64.9×1.22On target
214-ES-09, CórdobaRegional teaching hospital34.1×0.74Behind
214-ES-10, Santiago de CompostelaRegional teaching hospital86.5×1.22On target
214-ES-11, GranadaRegional teaching hospital65.5×1.09On target
214-ES-12, AlicanteCommunity hospital13.8×0.26Behind
214-ES-13, MadridCommunity specialist practice43.3×1.23On target
214-ES-14, MálagaSite new to research03.3×0.00Behind
214-ES-15, BarcelonaAcademic medical centre45.9×0.68Behind
214-ES-16, ZaragozaRegional teaching hospital14.8×0.21Behind
214-ES-17, PamplonaRegional teaching hospital114.6×2.40Ahead
214-ES-18, SalamancaDedicated research centre58.0×0.62Behind
214-ES-19, BilbaoSite new to research13.1×0.32Behind
214-ES-20, MurciaRegional teaching hospital46.5×0.62Behind
214-PL-01, RzeszówCommunity hospital65.1×1.19On target
214-PL-02, ZamośćSite new to research33.3×0.92On target
214-PL-03, ŁódźDedicated research centre136.1×2.12Ahead
214-PL-04, KrakówSite new to research25.2×0.39Behind
214-PL-05, WarsawDedicated research centre73.6×1.97Ahead
214-PL-06, BydgoszczSite new to research55.0×1.01On target
214-PL-07, PoznańAcademic medical centre102.8×3.58Ahead
214-PL-08, LublinRegional teaching hospital36.9×0.44Behind
214-PL-09, BiałystokDedicated research centre36.3×0.48Behind
214-PL-10, SzczecinDedicated research centre318.9×3.50Ahead
214-PL-11, GdańskCommunity hospital84.4×1.81Ahead
214-PL-12, OlsztynDedicated research centre167.3×2.20Ahead
214-PL-13, KatowiceDedicated research centre05.9×0.00Behind
214-PL-14, WrocławDedicated research centre138.7×1.50Ahead
214-PL-15, RzeszówSite new to research02.7×0.00Behind
214-PL-16, ZamośćSite new to research33.0×0.99On target
214-PL-17, ŁódźDedicated research centre27.0×0.29Behind
214-PL-18, KrakówCommunity specialist practice24.6×0.44Behind
214-PL-19, WarsawSite new to research32.9×1.02On target
214-PL-20, BydgoszczRegional teaching hospital36.9×0.43Behind
214-TR-01, DiyarbakırRegional teaching hospital02.5×0.00Behind
214-TR-02, AdanaSite new to research03.3×0.00Behind
214-TR-03, AnkaraAcademic medical centre25.0×0.40Behind
214-TR-04, İzmirAcademic medical centre06.7×0.00Behind
214-TR-05, MalatyaCommunity hospital43.6×1.11On target
214-TR-06, AntalyaSite new to research03.3×0.00Behind
214-TR-07, BursaRegional teaching hospital44.4×0.91On target
214-TR-08, AntakyaSite new to research93.6×2.49Ahead
214-TR-09, KayseriRegional teaching hospital47.1×0.57Behind
214-TR-10, GaziantepSite new to research13.2×0.31Behind
214-IN-01, DelhiCommunity specialist practice23.9×0.51Behind
214-IN-02, HyderabadCommunity specialist practice63.9×1.55Ahead
214-IN-03, KochiCommunity hospital66.2×0.97On target
214-IN-04, ChennaiAcademic medical centre145.0×2.82Ahead
214-IN-05, NagpurSite new to research33.6×0.83On target
214-IN-06, AhmedabadDedicated research centre49.3×0.43Behind
214-IN-07, LucknowCommunity specialist practice04.1×0.00Behind
214-IN-08, PuneSite new to research23.8×0.53Behind
214-IN-09, ChandigarhDedicated research centre68.9×0.68Behind
214-IN-10, BengaluruAcademic medical centre25.3×0.38Behind
214-IN-12, KolkataDedicated research centre53.0×1.68Ahead
214-IN-13, BhubaneswarRegional teaching hospital45.7×0.70Behind
214-IN-14, JaipurRegional teaching hospital05.3×0.00Behind
214-IN-15, MumbaiSite new to research154.1×3.65Ahead

Source: epiClinical synthetic sites. Left out: seven sites where fewer than two patients were expected so far, too few to judge.

Sites behind, and what might help

Largest shortfall first. Each site's screening log is split into three stages against the study as a whole; the stage marked is where it loses most. A likely cause needs both a leak at its stage and the fact that goes with it, so it was found for 35 of 60 sites. Suggestions wait for a person to accept or dismiss them. Nothing changes the plan on its own, and in a real system each decision is audit-logged.

Behind

214-TR-04, İzmir

Academic medical centre, Turkey · 0 randomised against 6.7 expected in 29 months open
  1. Approached×0.051 patient, 22 expected
  2. Agreed–1 patient approached, too few to judge
  3. Passed screening–1 patient screened, too few to judge
Likely cause
Competing trials take the same patients. The site approaches fewer patients than a site like it should, and runs other trials for the same patients. Investigators offer each patient one trial, so this study gets only a share of them. Known about this site: two or more competing trials open at the site.
Also known
Does not check records against the criteria before inviting patients.
  1. Agree with the investigator how patients are offered the competing trials.

    An operational step with no outcome evidence; it makes the site's choice visible.

  2. Central campaigns, recruitment vendors and referral networks. Referral routes from centres without the competing trials widen the pool.

    D Evidence grade D. No quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.

  3. Add sites or countries. If several sites share the problem, add sites where competition is lower.

    D Evidence grade D. No quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.

Behind

214-PL-13, Katowice

Dedicated research centre, Poland · 0 randomised against 5.9 expected in 20 months open
  1. Approached×0.163 patients, 19 expected
  2. Agreed–3 patients approached, too few to judge
  3. Passed screening–0 patients screened, too few to judge
Likely cause
Too little coordinator time. The site approaches fewer patients than a site like it should, and has little coordinator time for the study. Finding and approaching patients is usually the first task dropped when a coordinator is stretched or leaves. Known about this site: half a coordinator or less on this study.
  1. Increase site or investigator payments. Fund protected coordinator time, if the budget allows; there is no evidence it raises recruitment on its own.

    D Evidence grade D. No quantitative evidence for patient recruitment; a 2005 systematic review found almost no experimental evidence and raised conflict-of-interest concerns. One RCT of paying doctors concerned recruiting doctors as study subjects, not patient recruitment.

  2. Site re-training and extra site support visits. Extra CRA support visits while the site rebuilds its team.

    D Evidence grade D. No quantitative evidence found; the 2021 Cochrane retention review found only two studies targeting site staff.

  3. Close or replace non-enrolling sites. If the site still cannot staff the study after an agreed period, redirect the budget to a site that can.

    D Evidence grade D. No quantitative evidence on the effect of closing sites. Context only: 11% of activated sites enrol no one and 37% under-enrol (Tufts CSDD 2012 data).

Behind

214-IN-06, Ahmedabad

Dedicated research centre, India · 4 randomised against 9.3 expected in 29 months open
  1. Approached×0.8927 patients, 30 expected
  2. Agreed×0.7441%, study 55%
  3. Passed screening×0.6536%, study 56%
Likely cause
No stage stands out from the study; the shortfall may be chance or a cause not recorded here.
Also known
Screening scans are done at another hospital; Two or more competing trials open at the site.
  1. Screening-log review to find the leaking funnel stage. No known cause fits, so start by finding which stage loses patients and why.

    C Evidence grade C. No quantitative evidence that logs raise recruitment. In one oncology trial, logs showed 91% of eligible patients approached but 40% agreeing, pointing at the consent conversation; logs were incomplete (47% returned; 28% of enrolled patients missing).

Behind

214-IN-14, Jaipur

Regional teaching hospital, India · 0 randomised against 5.3 expected in 29 months open
  1. Approached×0.000 patients, 17 expected
  2. Agreed–0 patients approached, too few to judge
  3. Passed screening–0 patients screened, too few to judge
Likely cause
Too little coordinator time. The site approaches fewer patients than a site like it should, and has little coordinator time for the study. Finding and approaching patients is usually the first task dropped when a coordinator is stretched or leaves. Known about this site: half a coordinator or less on this study.
  1. Increase site or investigator payments. Fund protected coordinator time, if the budget allows; there is no evidence it raises recruitment on its own.

    D Evidence grade D. No quantitative evidence for patient recruitment; a 2005 systematic review found almost no experimental evidence and raised conflict-of-interest concerns. One RCT of paying doctors concerned recruiting doctors as study subjects, not patient recruitment.

  2. Site re-training and extra site support visits. Extra CRA support visits while the site rebuilds its team.

    D Evidence grade D. No quantitative evidence found; the 2021 Cochrane retention review found only two studies targeting site staff.

  3. Close or replace non-enrolling sites. If the site still cannot staff the study after an agreed period, redirect the budget to a site that can.

    D Evidence grade D. No quantitative evidence on the effect of closing sites. Context only: 11% of activated sites enrol no one and 37% under-enrol (Tufts CSDD 2012 data).

Behind

214-PL-17, Łódź

Dedicated research centre, Poland · 2 randomised against 7.0 expected in 24 months open
  1. Approached×0.6114 patients, 23 expected
  2. Agreed×1.0457%, study 55%
  3. Passed screening×0.4525%, study 56%
Likely cause
Patients wait too long for scans. Patients are failing screening more often than at other sites, and the screening scans are booked elsewhere. A slow scan can push a patient outside the screening window, so they fail on time rather than on eligibility. Known about this site: screening scans are done at another hospital.
Also known
Two or more competing trials open at the site.
  1. Agree protected research slots with the imaging provider.

    An operational step with no outcome evidence; check the screening log first to confirm patients are failing on the window.

  2. Screening-log review to find the leaking funnel stage. Confirms whether failures are timing or eligibility before money is spent on slots.

    C Evidence grade C. No quantitative evidence that logs raise recruitment. In one oncology trial, logs showed 91% of eligible patients approached but 40% agreeing, pointing at the consent conversation; logs were incomplete (47% returned; 28% of enrolled patients missing).

Behind

214-UK-14, Birmingham

Academic medical centre, United Kingdom · 0 randomised against 4.5 expected in 32 months open
  1. Approached×0.619 patients, 15 expected
  2. Agreed×0.2011%, study 55%
  3. Passed screening–1 patient screened, too few to judge
Likely cause
Patients decline because of the journey. Patients approached here agree to take part less often than elsewhere, and many live far from the site. The number of visits weighs more when each one is a long journey. Known about this site: two in five patients or more travel over an hour.
Also known
Does not check records against the criteria before inviting patients; Two or more competing trials open at the site.
  1. Participant payments or reimbursement. Reimburse travel, with ethics committee agreement.

    C Evidence grade C. Mixed in two RCTs: smoking-cessation trial consent 21.8% ($0) vs 35.9% ($200) vs 47.1% ($500); ambulation trial no effect (45.4%, 48.1%, 43.0%). No evidence of undue inducement in these low-risk trials.

  2. Add decentralised elements. Home nursing or remote visits for the visits that allow it; a study-wide change that needs an amendment.

    C Evidence grade C. Of 13 studies, 10 or 11 reported better recruitment with decentralised methods, mostly without head-to-head comparison; a 2022 systematic review found insufficient comparable data to say whether decentralised trials recruit or retain better.

Zero out of 113 judged sites are outside the range the planner's model allows by chance. Site rates vary so widely (coefficient of variation 0.9) that one site's shortfall is rarely proof of a problem. Behind is a prompt to look, not a verdict.

What sites behind have in common

Share of sites with each fact, by how they are doing. A fact far more common among sites behind is worth checking at feasibility for the next study. In this synthetic data the links were built in; with real data, this table is where they would first show.

FactAheadOn targetBehind
Does not check records against the criteria before inviting patients10%39%52%
Screening scans are done at another hospital7%4%17%
Half a coordinator or less on this study0%17%30%
Two or more competing trials open at the site3%9%33%
Relies on referrals, with no formal referral network0%0%10%
Two in five patients or more travel over an hour0%9%20%

Every site

Show all 120 sites
SiteProfileMonths openExpectedRandomisedApproachedScreenedPassed screeningStanding
214-US-01, San DiegoCommunity specialist practice28.03.7111100%Behind
214-US-02, Los AngelesSite new to research29.93.525367%Behind
214-US-03, BaltimoreSite new to research32.53.14161040%Ahead
214-US-04, AtlantaCommunity specialist practice32.83.119250%Behind
214-US-05, BostonAcademic medical centre29.91.90320%Too early
214-US-06, New YorkDedicated research centre32.35.125450%Behind
214-US-07, DenverCommunity specialist practice27.71.30110%Too early
214-US-08, MiamiDedicated research centre31.34.9213540%Behind
214-US-09, NashvilleCommunity hospital27.54.18271457%Ahead
214-US-10, ClevelandRegional teaching hospital29.13.70520%Behind
214-US-11, Salt Lake CitySite new to research27.12.2412667%Ahead
214-US-12, DallasCommunity specialist practice31.13.0510771%Ahead
214-US-13, SeattleRegional teaching hospital28.25.0217540%Behind
214-US-14, PhoenixDedicated research centre28.54.526633%Behind
214-US-15, MinneapolisRegional teaching hospital30.41.915250%Too early
214-US-16, CharlotteCommunity specialist practice29.71.4020–Too early
214-US-17, ChicagoSite new to research32.33.80310%Behind
214-US-18, PhiladelphiaDedicated research centre27.44.30720%Behind
214-US-19, PittsburghRegional teaching hospital28.25.017333%Behind
214-US-20, HoustonCommunity hospital31.14.78201173%Ahead
214-US-21, San DiegoRegional teaching hospital32.44.17221450%Ahead
214-US-22, Los AngelesSite new to research30.92.9000–Behind
214-US-23, BaltimoreCommunity specialist practice28.13.70110%Behind
214-US-24, AtlantaSite new to research31.92.3171100%Behind
214-US-25, BostonAcademic medical centre30.33.815425%Behind
214-US-26, New YorkDedicated research centre29.46.513392162%Ahead
214-US-27, DenverDedicated research centre31.34.95171242%On target
214-US-28, MiamiCommunity hospital32.53.58221362%Ahead
214-US-29, NashvilleSite new to research27.82.60630%Behind
214-US-30, ClevelandRegional teaching hospital32.12.00310%Behind
214-US-31, Salt Lake CitySite new to research32.52.324367%On target
214-US-32, DallasDedicated research centre28.54.5411667%On target
214-US-33, SeattleDedicated research centre30.32.4311743%Ahead
214-US-34, PhoenixCommunity hospital32.64.919617%Behind
214-US-35, MinneapolisDedicated research centre30.34.87137100%Ahead
214-US-36, CharlotteCommunity hospital31.53.45201050%Ahead
214-US-37, ChicagoCommunity hospital28.93.10710%Behind
214-US-38, PhiladelphiaCommunity hospital27.83.0000–Behind
214-US-39, PittsburghDedicated research centre27.74.418520%Behind
214-US-40, HoustonAcademic medical centre28.71.8411667%Too early
214-UK-01, NottinghamCommunity hospital28.53.4417757%On target
214-UK-02, EdinburghRegional teaching hospital29.14.2211540%Behind
214-UK-03, LeedsSite new to research30.82.835475%On target
214-UK-04, SheffieldRegional teaching hospital27.63.99191182%Ahead
214-UK-05, LondonCommunity hospital33.05.67231644%On target
214-UK-06, NewcastleRegional teaching hospital31.24.5410757%On target
214-UK-07, BristolSite new to research27.02.9010–Behind
214-UK-08, LiverpoolRegional teaching hospital32.24.6312743%Behind
214-UK-09, OxfordSite new to research30.53.328450%Behind
214-UK-10, CardiffRegional teaching hospital28.14.06181155%Ahead
214-UK-11, CambridgeCommunity hospital29.01.826367%Too early
214-UK-12, ManchesterAcademic medical centre28.94.14124100%On target
214-UK-13, SouthamptonRegional teaching hospital31.24.55251242%On target
214-UK-14, BirminghamAcademic medical centre31.54.50910%Behind
214-UK-15, GlasgowCommunity hospital32.43.9611875%Ahead
214-ES-01, ZaragozaRegional teaching hospital28.02.4513863%Ahead
214-ES-02, PamplonaRegional teaching hospital24.74.1210450%Behind
214-ES-03, SalamancaRegional teaching hospital25.62.2050–Behind
214-ES-04, BilbaoSite new to research24.43.111271765%Ahead
214-ES-05, MurciaSite new to research28.83.1616875%Ahead
214-ES-06, OviedoSite new to research26.33.349667%On target
214-ES-07, ValenciaCommunity hospital26.35.3217633%Behind
214-ES-08, SevilleAcademic medical centre29.24.9623875%On target
214-ES-09, CórdobaRegional teaching hospital24.24.13161127%Behind
214-ES-10, Santiago de CompostelaRegional teaching hospital27.86.58231362%On target
214-ES-11, GranadaRegional teaching hospital23.55.5621967%On target
214-ES-12, AlicanteCommunity hospital26.43.8110425%Behind
214-ES-13, MadridCommunity specialist practice25.83.3411667%On target
214-ES-14, MálagaSite new to research26.23.30220%Behind
214-ES-15, BarcelonaAcademic medical centre25.05.9420944%Behind
214-ES-16, ZaragozaRegional teaching hospital28.74.814250%Behind
214-ES-17, PamplonaRegional teaching hospital27.34.611211385%Ahead
214-ES-18, SalamancaDedicated research centre27.38.0519956%Behind
214-ES-19, BilbaoSite new to research25.03.1181100%Behind
214-ES-20, MurciaRegional teaching hospital27.56.54251429%Behind
214-PL-01, RzeszówCommunity hospital25.35.16251250%On target
214-PL-02, ZamośćSite new to research21.83.3313560%On target
214-PL-03, ŁódźDedicated research centre20.96.113261968%Ahead
214-PL-04, KrakówSite new to research23.55.227367%Behind
214-PL-05, WarsawDedicated research centre24.23.67191164%Ahead
214-PL-06, BydgoszczSite new to research22.55.0513863%On target
214-PL-07, PoznańAcademic medical centre23.72.810181471%Ahead
214-PL-08, LublinRegional teaching hospital20.96.9310650%Behind
214-PL-09, BiałystokDedicated research centre21.46.337560%Behind
214-PL-10, SzczecinDedicated research centre21.58.931674766%Ahead
214-PL-11, GdańskCommunity hospital22.14.48241553%Ahead
214-PL-12, OlsztynDedicated research centre24.77.316412370%Ahead
214-PL-13, KatowiceDedicated research centre20.05.9030–Behind
214-PL-14, WrocławDedicated research centre21.18.713362357%Ahead
214-PL-15, RzeszówSite new to research20.32.7000–Behind
214-PL-16, ZamośćSite new to research22.93.0312475%On target
214-PL-17, ŁódźDedicated research centre23.87.0214825%Behind
214-PL-18, KrakówCommunity specialist practice25.94.628540%Behind
214-PL-19, WarsawSite new to research22.32.9383100%On target
214-PL-20, BydgoszczRegional teaching hospital21.16.93141030%Behind
214-TR-01, DiyarbakırRegional teaching hospital30.32.5010–Behind
214-TR-02, AdanaSite new to research26.03.30630%Behind
214-TR-03, AnkaraAcademic medical centre29.55.0210450%Behind
214-TR-04, İzmirAcademic medical centre28.66.70110%Behind
214-TR-05, MalatyaCommunity hospital25.33.6414757%On target
214-TR-06, AntalyaSite new to research30.63.30310%Behind
214-TR-07, BursaRegional teaching hospital26.24.4410757%On target
214-TR-08, AntakyaSite new to research28.73.69251275%Ahead
214-TR-09, KayseriRegional teaching hospital30.17.1412757%Behind
214-TR-10, GaziantepSite new to research30.23.216250%Behind
214-IN-01, DelhiCommunity specialist practice28.23.9210633%Behind
214-IN-02, HyderabadCommunity specialist practice27.83.9615967%Ahead
214-IN-03, KochiCommunity hospital28.06.26201155%On target
214-IN-04, ChennaiAcademic medical centre26.85.014271974%Ahead
214-IN-05, NagpurSite new to research30.53.638560%On target
214-IN-06, AhmedabadDedicated research centre28.99.34271136%Behind
214-IN-07, LucknowCommunity specialist practice29.54.10320%Behind
214-IN-08, PuneSite new to research27.43.827450%Behind
214-IN-09, ChandigarhDedicated research centre27.48.96251250%Behind
214-IN-10, BengaluruAcademic medical centre28.55.329540%Behind
214-IN-11, VelloreCommunity specialist practice25.11.70210%Too early
214-IN-12, KolkataDedicated research centre25.73.05141050%Ahead
214-IN-13, BhubaneswarRegional teaching hospital30.95.7411850%Behind
214-IN-14, JaipurRegional teaching hospital28.65.3000–Behind
214-IN-15, MumbaiSite new to research29.64.115321788%Ahead

Rules behind this page

  • A site that has recruited below this share of its expected count is behind: 75%. epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01).
  • A site that has recruited above this share of its expected count is ahead: 125%. epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8).
  • Patients a site must have been expected to recruit before it is judged: 2. epiClinical assumption: below this, a site's count says more about chance than about the site.
  • Patients offered a trial who agree to take part: 55%. 55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155).
  • Patients needed at a funnel stage before a site's rate there is compared with the study's: 8. epiClinical assumption: with fewer, a single patient moves the rate by more than ten points.
  • A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this: 0.1. epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement.
  • Patients fail screening: Screen failure is high and varies widely by therapeutic area (register PM-05); restrictive criteria are the commonest design barrier (PB-02, PD-01).
  • Patients wait too long for scans: epiClinical assumption from CRA practice; procedures per protocol rose 40.6% since 2010, which weighs on sites without services on site (register S-24).
  • Too little coordinator time: Coordinator turnover of 10 to 37% a year, rising to 35 to 61% in 2022; 45% of sites say capacity limits new studies (register S-09, S-11).
  • Competing trials take the same patients: Competing trials for the same patients reduce enrolment where the eligible pool is scarce (register EB-02, S-21).
  • Too few patients referred: Research-focused sites recruit about 41% better, but depend on referral routes (register S-07); referral networks lack outcome evidence (action A14).
  • Patients decline because of the journey: Procedural and visit burden lowers enrolment and retention (register PD-03); decentralised elements help mainly where travel is the barrier (PD-20).